Originally published in "Discussions with Don S. Dizon" on The Oncologist
One of the questions that I face (and which I am certain many of us do) concerns the use of alternative therapies. Iron chelation therapy, high-dose vitamin C infusions, Chinese herbs—interest in these therapies and others like them are driven by word of mouth (“a friend of a friend”), claims on websites, and patients’ own curiosity. Cancer is serious, and let’s face it—modern medicine has not (yet) found the cure.
What usually follows is a Western medicine-driven explanation—that as physicians, we seek to uphold the Hippocratic Oath: to “first, do no harm” and to understand the diseases we treat and the medications we use. More than that, we seek evidence—of benefit and potential harms of proposed therapies. Indeed, evidence-based medicine has become the mantra that guides many of our decisions. Certainly, there is no uniformity in evidence. I am the first to admit that not all treatments I use are backed by evidence from a randomized clinical trial, the gold standard that applies to much of medicine, and certainly, to oncology. So physicians rely on the perceived best evidence we can find: systematic reviews, observational studies, clinical guidelines and expert opinions, and occasionally, anecdotes and case reports.
When it comes to many alternative therapies, the data is too sparse to inform discussions on benefits and/or risks. Once, early in my career, I tried to study Essiac, an herbal remedy that a patient of mine had taken. There was so little data that I had to apply for an Investigational New Drug (IND) application with the U.S. Food and Drug Administration. Sadly, the project was terminated due to lack of interest—I could not find women willing to be randomly assigned to Essiac or to placebo. Hence, my firsthand experience with lack of evidence when it comes to these treatments.
For most patients, it seems that my explanation is sufficient and they proceed with standard (or evidence-based) therapy. Others make an informed choice and initiate alternative treatment with my knowledge, so we can watch for drug interactions and toxicities. I am aware, however, that there is another group, the one that decides to try alternative treatment but does not want me to know. Perhaps it is because they sense I will be against it or because they do not want to “disappoint” me. But I know some of my patients take treatments without my knowledge—I just never know which ones they are.
The last time I thought about this issue, I was treating a young woman for uterine cancer. She had undergone surgery, chemotherapy, and radiation for a high-grade, early-stage tumor and had done well for about 2 years—until she presented with vaginal bleeding and was found to have metastatic disease. She was devastated that her tumor had returned and was less than confident that traditional approaches would help. She started doing research online and discovered alternative options, natural medicines and alternative approaches to treatment available internationally. I encouraged her to consider a clinical trial and offered her one available at our center—it was testing a novel antibody drug conjugate that had showed promise in other tumors. After much discussion, she chose to pursue the clinical trial.
“Can I take other medications?” she asked.
“Well, it depends. What kind?” I asked.
“I would like to try a vitamin and herbal combination that someone told me about.”
“Unfortunately, the protocol does not allow you to take alternative or integrative therapies. We do not know about the safety of other medications, especially with a drug that is still being tested.”
“Oh, OK,” she said.
I presumed the issue was resolved, so we went about enrollment and she started on the trial. After two cycles, she had experienced a partial response; by the fourth cycle, she appeared to be veering toward remission. I was elated with these results, and she was too. Following her fourth treatment, however, she called complaining of profound shortness of breath. Looking back, it had been gradual—the effort required to climb a flight of stairs slowly had been increasing, though she never complained of it at the time. Now, she could only take four or five steps before experiencing dyspnea. I was alarmed and brought her in to the clinic where a chest X-ray showed diffuse interstitial infiltrates consistent with pneumonitis.
I looked back at the consent form. This was not listed as a known toxicity, not even among “rare” side effects. I asked her if anything had been different in the past month; had she started taking any medication? Travelled anywhere on her off weeks?
“Well, I did start taking herbal supplements last month,” she said.
I looked at her a little dumbfounded. “What kinds of supplements?”
She named off a list of 15 supplements, many of which I had never heard of. As she did, I became angry. Not because she had taken these treatments, but because she did so when it was expressly forbidden as part of the trial… and also because she never told me.
“It’s possible that what’s happening to your lungs is due to the drug, though it has not been reported that I can see. But it’s also possible that any of these supplements could have caused the issue—by itself or through an interaction with the drug we are trying for your cancer,” I told her, trying not to sound angry.
She started to cry then. “I never imagined that my supplements could cause a problem. They’re natural and I didn’t need a prescription or anything for them—and what I saw on the Web made them sound so helpful.”
“Well, for now, we need to stop them, and we need to hold off on the trial therapy,” I told her. “I want to see you weekly so I can make sure things get better, which I hope will happen.”
“OK,” she said.
It took time, but she did get better. Unfortunately, the delay from waiting for her lung function to improve was too long, and we were forced to withdraw from the trial due to toxicity. In the end, I could not be sure what had caused her lung function to deteriorate. But, as uncertain as I am about that, I am also sad that the possibility of using a drug that seemed to be working was now gone. True, she could have progressed within a few months, but she also could have entered a remission, that all too infrequent endpoint patients—and their physicians—hope for.